What's new

Human medicines European public assessment report (EPAR): Amgevita, adalimumab, Date of authorisation: 21/03/2017, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Amgevita, adalimumab, Date of authorisation: 21/03/2017, Revision: 14, Status: Authorised

Mar 31, 2025 - 15:12
 0
Human medicines European public assessment report (EPAR): Amgevita, adalimumab, Date of authorisation: 21/03/2017, Revision: 14, Status: Authorised
Human medicines European public assessment report (EPAR): Amgevita, adalimumab, Date of authorisation: 21/03/2017, Revision: 14, Status: Authorised
Read More

Tags:

Previous Article

Merck's Winrevair slashes mortality-morbidity risk by 76%

Next Article

Unraveling the Dynamic Transformation of Azobenzene-driven Redox Electrolytes fo...

Related Posts

Veterinary medicines European public assessment report (EPAR): Vectormune HVT-AIV, Avian influenza vaccine, Status: Opinion

Veterinary medicines European public assessment report ...

Feb 14, 2025  0

Human medicines European public assessment report (EPAR): Biktarvy, bictegravir,emtricitabine,tenofovir alafenamide, Date of authorisation: 21/06/2018, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 27, 2025  0

Budesonide, gastro-resistant hard capsules, 3 mg, gastro- resistant granules, 9 mg product-specific bioequivalence guidance

Budesonide, gastro-resistant hard capsules, 3 mg, gastr...

Feb 12, 2025  0